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ABSTRACT
Background: Contacts of patients with active tuberculosis
(“TB contacts”) with a tuberculin skin test (TST) size5 mm
are currently recommended treatment for latent TB infection
(LTBI). Knowing the cost-effectiveness of LTBI therapy for
speciﬁc TB contact subpopulations may improve the use of
limited resources by reducing the treatment of persons at low
TB risk.
Objective: To evaluate the cost-effectiveness of LTBI therapy
for different TB contact populations deﬁned by important
risk factors, and to propose an optimal policy based on
different recommendation for each subgroup of contacts.
Methods: A 6-year Markov decision analytic model simulat-
ing the quality-adjusted life years (QALYs), number of active
TB cases prevented, and costs for hypothetical cohorts of
Canadian TB contacts deﬁned by TST size, age group
(<10 y/o or above), ethnicity, closeness of contact, and
Bacillus Calmette-Guérin (BCG) vaccination status.
Results: For the majority of subgroups, the current policy of
preventive therapy in those with positive TST was the most
cost-effective. Nevertheless, our analysis determined that
LTBI treatment is not cost-effective in nonhousehold
Canadian-born (nonaboriginal) or foreign-born contacts age
10 y/o. On the other hand, empirical treatment without
screening of all non-BCG-vaccinated household contacts age
<10 y/o appeared cost-effective. Such an optimal approach
would result in an incremental net monetary beneﬁt of $25
for each contact investigated for a willingness-to-pay of
$50,000/QALY. Results were robust to several alternative
assumptions considered in sensitivity analyses.
Conclusions: The current practice of LTBI treatment for TB
contacts with a TST size 5 mm is cost-effective. A custom-
ized approach based on excluding low risk groups from
screening and providing treatment to high risk contacts
without screening could improve the performance of the
program.
Keywords: tuberculosis, contact tracing, cost-beneﬁt analy-
sis, tuberculin test, diagnosis.
Introduction
The incidence of tuberculosis (TB) in North America
has declined considerably since its resurgence in the
late 1980s [1,2], but progress toward TB elimination
has slowed in recent years [3]. TB’s threat is focused
today in subpopulations at elevated risk of advancing
from latent TB infection (LTBI) to active TB disease,
such as persons recently exposed to patients with in-
fectious TB disease (“TB contacts”). In the USA and
Canada, currently TB management guidelines support
tuberculin skin testing to identify persons with LTBI in
such contacts, and provide them preventive treatment
[4,5].
Cost-effectiveness analysis (CEA) offers a valuable
framework for evaluating health-care policies on
health outcomes and costs together. There have been
many CEAs of the treatment of, and/or screening for,
LTBI in populations such as intravenous drug users
[6,7], the elderly [8], tuberculin reactors stratiﬁed by
age [9,10], and immigrants [11–14]. So far, none have
evaluated TB health outcomes in the holistic way
recommended by the inﬂuential US Panel on Cost-
Effectiveness in Health and Medicine [15]. The panel
advocates health outcome measurement in quality-
adjusted life years (QALYs) constructed from quality
of life weights, or utilities, elicited from TB patients.
Address correspondence to: Carlo A. Marra, CORE, 2146 East
Mall, Faculty of Pharmaceutical Sciences, University of British
Columbia, Vancouver, BC V6T 1Z3, Canada. E-mail:
carlo.marra@ubc.ca
10.1111/j.1524-4733.2008.00334.x
Volume 11 • Number 5 • 2008
V A L U E I N H E A LT H
842 © 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/08/842 842–852
Another general limitation is that CEAs have often
failed to evaluate the beneﬁt of treatment in subgroups
of contacts with a combination of factors such as prior
Bacillus Calmette-Guérin (BCG) vaccination and eth-
nicity [16–19].
The present study examines the cost-effectiveness of
LTBI treatment for hypothetical cohorts of TB contacts
deﬁned by tuberculin skin test (TST) size and several
known risk factors for progression to active TB.
Health outcomes included QALYs which were calcu-
lated according to US Panel recommendations,
although TB risk estimates were adjusted for impor-
tant confounders relating to demographic proﬁle, clini-
cal presentation, and medical history.
Methods
Our decision analytic model was developed with
DATA 4.0 (TreeAge Software, Williamstown, MA,
USA). The time horizon was 6 years, the average
follow-up length of TB contacts in BC, for which the
relative risk of covariates for TB reactivation was esti-
mated [20]. The base-case analysis considers costs and
effectiveness from a societal perspective. A Canadian
third-party payer’s (governmental) perspective was
explored in sensitivity analyses. A schematic illustra-
tion of the model is shown in Figure 1. Key model
assumptions are shown in Table 1.
The study investigated hypothetical cohorts of TB
contacts deﬁned by several attributes known to affect
TST results or risk of TB reactivation: household
versus nonhousehold contacts, prior history of BCG
vaccination, age group (<10 y/o vs. older), and ethnic-
ity (foreign-born, aboriginal, and Canadian-born non-
aboriginal). The choices of the covariates were based
on their known effect on TST results or risk of infec-
tion, and the distribution of the covariate in the popu-
lation such that an alternative policy based on that
covariate would apply to a signiﬁcant fraction of con-
tacts. TB contacts with previous TB disease or HIV
infection were excluded for being at signiﬁcantly dif-
ferent risk of TB [18].
The screening test evaluated here was TST, and in
line with Canadian and American guidelines, a positive
test was deﬁned as a TST 5 mm in either of the ﬁrst,
usually immediately after diagnosis of the index TB
case or the second TST usually planted 8 to 12 weeks
later [5,31]. The treatment was deﬁned as the stan-
dard, 9-month course of isoniazid. Cost-effectiveness
was measured in terms of incremental cost per QALY
gained or per active TB case prevented. Future costs
and health outcomes were discounted at an annual rate
of 3%.
Interventions and Policies
An intervention is deﬁned as a screening approach to a
speciﬁc subgroup of contacts. Three possible interven-
tions investigated here were:
1. No screening: not screening contacts and not
offering preventive therapy;
2. Test and treat: testing contacts and treating those
with a positive test;
3. Treat all: offering preventive therapy to all con-
tacts in the subgroup without testing.
A policy is deﬁned as a screening approach applied
to the whole population of contacts based on speciﬁc
interventions for each subgroup. A policy might rec-
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Figure 1 Illustration of the model. On the left hand side, the decision tree displays the four different combinations of TST size and LTBI treatment. In
addition, the probabilities of major adverse events, completing treatment, and survival are mapped in the model.On the right, theTB reactivation submodel
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ommend no screening in some contacts, test, and treat
is some others, and treat without screening in the
remainder of contacts. In this analysis, the perfor-
mance of three screening policies is evaluated:
1. No screening: applying the no screening interven-
tion to all contacts;
2. Current (test and treat) policy: based on test and
treat intervention in all contacts;
3. Optimal policy: the policy that selects the most
cost-effective intervention for each subgroup of
contacts.
Evaluation of Health Outcomes
Transition probabilities. Risk of TB development for
each subgroup of contacts was estimated from a large,
population-based provincial registry of TB contacts in
British Columbia [32]. To capture the occurrence of
active TB in contacts, records from a 12-year period
(1990–2001) were extracted. Overall, data from more
than 19,000 contacts were matched, with average
follow-up of 6 years (maximum 12.5 years). A propor-
tional hazards (Cox) regression model was built to
estimate the multivariate, adjusted hazard ratio of
covariates on the risk of TB development. For each
study cohort, we modeled the 6-year cumulative inci-
dence of active TB according to general formula:
(TB hazard in the reference group) ¥ (TB hazard ratio
associated with a given covariate) ¥ (Effectiveness of
LTBI treatment) ¥ (TB hazard ratio associated with
positive/negative TST)
All components of the above formula were derived
from a Cox proportional hazard model of TB inci-
dence [33]. The reference group was deﬁned as
Canadian-born, nonaboriginal, nonhousehold con-
tacts aged 10 years and older without previous BCG.
Age-speciﬁc, all-cause mortality in the model was
based on Canada Life Tables [34]. All-cause mortality,
and TB-related mortality, was modeled as being higher
in aboriginal persons [29]. Mortality from a major
adverse reaction to LTBI therapy or TB disease was
also taken into account as described in the literature
(see Table 1).
Health state utilities and QALYs. Key assumptions
relating to the construction of QALYs are presented in
Table 1 Transition probabilities
Description of variable Base value Distribution type Source
Six-year risk of TB in the reference group with a TST size <5 mm:
Canadian-born, nonaboriginal TB contacts older than 10 years
with no immunosuppressive conditions or high-risk behavior; no
BCG vaccination; and no LTBI treatment
0.81 [0.60–0.91]
per 100,000
Nonparametric
bootstrap
Cox regression [20]
Hazard ratio associated with the following TB contact
proﬁle characteristics:
Age 0–10 years 14.71 [10.4–20.8] Log normal Cox regression [20]
Aboriginal status 1.95 [1.38–2.77] Log normal Cox regression [20]
Foreign-birth 0.4 [0.27–0.59] Log normal Cox regression [20]
BCG vaccination 0.24 [0.16–0.35] Log normal Cox regression [20]
Household contact 7.26 [4.69–11.26] Log normal Cox regression [20]
TST 5 mm 149.5 [85.6–243.2] Log normal Cox regression [20]
Reduction in TB incidence because of LTBI treatment
Partially completed treatment 65% [60–71%] Log normal Cox regression [20]
Completed treatment 94% [88–97%] Log normal Cox regression [20]
Secondary transmission
Infected contacts per diagnosed index case 3.5 Fixed a value [21,22]
Cases of active TB per index case 0.3 [0.2–0.5] Log normal [23,24]
LTBI treatment
Probability of completing at least 6 months of isoniazid 0.61 [0.59–0.63] Binomial BCCDC
Probability of major adverse reaction to isoniazid 0.003 Fixed value* [10,25]
Mortality given major side effect and inactive TB in persons
without TB disease
0.015 Fixed value [10,25,26]
TB disease treatment
Probability of hospitalization following from progression to
and diagnosis of active TB
0.8 Fixed value [27]
One-year mortality given treatment of active TB Ages 15–24: 0.004 Fixed value [28]
Ages 25–34: 0.015
Ages 35–44: 0.046
Relative risk of all-cause mortality relative to reference group for
the following TB contact proﬁles:
Aboriginal status 2.0 [1.8–2.3] Log normal [29]
All other TB cohorts 1 Fixed value Assumption
Relative risk of TB-attributable mortality relative to reference group
Malnutrition 3.2 [2.1–4.9] Log normal [30]
All other TB cohorts 1 Assumption
*In one-way sensitivity analysis with respect to different start ages, the risk of a major adverse reaction was increased by a factor of 1.9 to individuals aged 35 years and older.
BCG, Bacillus Calmette-Guérin; LTBI, latent tuberculosis infection;TST, tuberculin skin test.
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Table 2. Utility values were assigned to the TB health
states: “no infection” in the absence of LTBI treatment
and active TB; treatment of LTBI in the absence of any
major adverse reaction; treatment of LTBI resulting in
a major adverse reaction; and active TB. Utilities were
elicited with Short Form 6D (SF-6D) and Health Utili-
ties Index-3 (HUI-3) questionnaires given to 119
patients with LTBI, and 114 patients with active TB
recruited through British Columbia Centre for Disease
Control (BCCDC) TB clinics in 2004 to 2005 [35].
The SF-6D utilities were used in the base-case
analysis, and the HUI-3 values in sensitivity analysis.
None of the patients in the above study experienced a
major hepatotoxic adverse event. For this health state,
we referred to a published SF-6D utility estimate
derived from a sample of liver transplant patients
(0.61, SD 0.01) [36]. Time spent in these health states
was determined from another TB CEA and permitted
the calculation of QALYs [8].
Secondary transmission. In the base-case analysis, we
assumed that each case of active TB would result in an
additional 0.3 active TB cases, and 3.5 infected con-
tacts because of secondary transmission [21–24]. We
considered each secondary case of active TB to result
in a decrement of 0.1 QALY which approximates the
average loss of QALYs in primary active TB patients in
the model.
Evaluation of costs. Resource utilization was adapted
from the Canadian literature and modiﬁed to account
for differences in TB management guidelines, local
practices, and setting [14,37]. Our model accounted
for physician visits, LTBI treatment, hospitalizations,
the diagnosis and management of contacts with active
TB, contact investigations, and the management of TB
contacts with either LTBI or active TB disease identi-
ﬁed through contact investigations.
Cost data were obtained from the BCCDC and the
British Columbia Medical Association 2004 Medical
Services Plan payment schedule for medical practitio-
ners [38]. Hospital costs were provided by a model
developed at a large tertiary referral hospital in Van-
couver. All costs were evaluated in Y2003 Canadian
dollars (Table 3). The fully allocated cost of TST
screening was only applied to the test and treat inter-
vention as the no screening and treat all interventions
do not require a screening test.
Cost-effectiveness evaluation. In the base-case analy-
sis, we assessed the incremental cost-effectiveness of
the test and treat versus no screening intervention and
that of the treat all versus the test and treat interven-
tion for each subgroup of contacts deﬁned by combi-
nation of covariates. Based on these results, an optimal
policy was composed by choosing the most cost-
effective intervention for each subgroup. The most
cost-effective intervention was deﬁned as one that has
the highest net monetary beneﬁt (NMB) at the willing-
ness to pay value of $50,000 per QALY. The cost-
effectiveness of the optimal policy was compared with
the current policy and also with the no screening
policy.
Probabilistic sensitivity analysis (PSA). Uncertainty in
the cost-effectiveness of the optimal policy was
addressed with probabilistic analysis involving second-
order Monte Carlo simulations of 1000 trials (i.e.,
Table 2 Assumptions for utilities and time spent in tuberculosis (TB) health states*
Health state SF-6D utility HUI-3 utility
Model assumptions relating to
duration spent in health states
Source of
utility estimates
LTBI therapy with no major
adverse reaction
Beta distribution with a mean
of 0.83 (SD 0.12)
minus
0.02
Beta distribution with a mean
of 0.92 (SD 0.18)
minus
0.02
3 months (if patient is
noncompliant)
9 months (if patient is
compliant)
[37]
Major adverse (hepatotoxic)
reaction during LTBI
treatment
Beta distribution with a mean
of 0.83 (SD 0.12)
minus
0.20‡
Beta distribution with a mean
of 0.92 (SD 0.18)
minus
0.31†
2 months (if patient survives)
1 month (if patient dies)
[38]
TB disease Beta distribution with a mean
of 0.83 (SD 0.12)
minus
0.13†
Beta distribution with a mean
of 0.92 (SD 0.18)
minus
0.16†
6 months (if patient survives)
3 months (if patient dies)
[37]
“No infection” (no TB disease
or LTBI therapy)
Beta distribution with a mean
of 0.83 (SD 0.10)‡
Beta distribution with a mean
of 0.92 (SD 0.18)
Remainder of time while alive [37]
Death 0 0 By deﬁnition
*The change in QALYs because of secondary TB cases (arising when a TB contact progresses to active TB) was -0.1, under the assumption that all secondary cases receive
successful treatment for TB disease.
†In the base-case analysis, the utility value associated with being on LTBI treatment was set as a ground value (with a beta probabilistic distribution) used in constructing the utility
values for the other health states.We used the formula: utility of health state X = ground value + (expected value for the utility of being in health state X – expected value for
the ground value). In one-way sensitivity analysis, all utility values were given independent beta distributions.The mean utility associated with a major adverse reaction was 0.61
(SD 0.01).The mean utility associated with TB disease was 0.68 (SD 0.15).
‡In one-way sensitivity analysis, the utility of no infection was allowed to differ from 1.The new value, 0.83 (SD 0.10), was determined from LTBI patients who reported no ill
effects from LTBI therapy.
HUI-3, Health Utilities Index-3; LTBI, latent tuberculosis infection; SF-6D, Short Form 6D.
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draws from probability distributions given to key
model parameters). Parameters for distributions were
estimated from the literature and, for the results of the
Cox proportional hazards model, from the covariance
matrix of the regression coefﬁcients. Uncertainty in
costs was modeled by assigning triangular distribution
ranging from 25% lower to 25% higher of the point
estimate. Like the base case analysis, the cost, QALY,
and prevented TB cases were calculated for each sub-
group at each run of the second-order simulation, and
the outcomes for the optimal policy was calculated
accordingly. For all subgroups, the second-order simu-
lation was performed using the same random-number
seed so that the correlation among the estimates of
outcomes in subgroups is preserved in calculating the
cost and effectiveness of the policies.
Results of this analysis are presented as plots of
the cost-effectiveness plane and as cost-effectiveness
acceptability curves (CEAC), and the latter illustrates
the probability of treatment cost-effectiveness for a
range of willingness-to-pay (WTP) values. In compar-
ing policies when health outcomes were in QALYs,
$50,000 per QALY gained was chosen as WTP
threshold according to endorsed values in the literature
[39,40].
In the base case analysis, utility estimates of active
TB, LTBI treatment without major adverse reaction,
and no infection were modeled to be positively corre-
lated. This was necessary to avoid nonplausible com-
binations such as utility of patients with LTBI being
lower than those with active TB. In a separate PSA, we
relaxed the assumption of positive correlation among
the utilities.
One-way sensitivity analysis. The robustness of the
base-case ﬁndings with respect to different model
assumptions was assessed with one-way sensitivity
analysis. One at a time, we changed analytic perspec-
tive (to a third-part payer one, excluding indirect
costs), Markov time horizon, initial cohort age, dis-
count rate, and compliance with LTBI therapy. The
impact of choosing HUI-3 utility estimates instead of
SF-6D utilities was also analyzed. Results of the one-
way sensitivity analysis are based on QALY as the
health outcome. To avoid confusion in comparing
negative incremental cost effectiveness ratios (ICERs),
results are presented in terms of incremental NMB for
the current policy versus no screening and for the
optimal policy versus the current policy in the whole
population of contacts at WTP of $50,000/QALY.
Results
Base-Case Findings
The combination of four covariates created 24 sub-
groups of contacts. Of these, 11 comprised less than
5% of contacts and hence their outcome is not
reported. The base-case results for the remaining 13
groups, which comprised 95% of all contacts, are sum-
marized in Table 4.
When QALYs were used as the health outcome
measure, the test and treat intervention was the most
cost-effectiveness intervention compared with no
screening or treat all interventions in the majority
of subgroups. There were important exceptions,
however: for the nonaboriginal Canadian-born, and
for the foreign-born individuals, when both are casual
(nonhousehold) contacts older than 10 years, the no
screening intervention was the best option (regardless
of BCG status). On the other hand, for the household
contacts age <10 years and without BCG vaccination,
the treat all intervention was the best option. The
subgroups for which the test and treat intervention
was not the best option overall comprised more than
60% of contacts (Table 4).
Results were almost the same when active TB cases
prevented were used as the health outcome measure.
For the groups for which no treatment was the most
cost-effective bases on QALY, the cost per avoiding an
Table 3 Summary/key cost assumptions forVancouver General
Hospital/British Columbia Resource Utilization Model (Y2003
Canadian dollars)*
Variable Base value
Selected cost components
Cost of chest x-ray (postereoanterior and lateral
chest x-ray)
$31.21
Cost of tuberculin test (including injection and
reading)
$15.42
Cost of initial (outpatient clinic) evaluation $62.03
Cost of further workup for abnormal chest x-ray
(three sputa and one follow-up visit)
$128.39
Cost of 9-month course of INH, after initial
evaluation
$270.61
Cost of AST test $15/each
Duration of hospitalization for hospitalized active
TB cases
19 days
Fully allocated costs per day of hospitalization $570/day
Percent of active TB cases requiring hospital
admission (passive diagnosis)
80%
Cost subtotals
LTBI treatment (complete) $385
LTBI treatment (incomplete because of
noncompliance)
$158
Major adverse reaction to LTBI treatment $582
Surveillance of TB contacts for whom LTBI
treatment is indicated but who do not initiate
$236
Active TB treatment
Inpatient $13,334
Outpatient $908
Contact investigation (per index case) $770
Diagnosis of a TB contact with LTBI (one clinic
evaluation, one chest x-ray, and one tuberculin
skin test plus follow-up)
$130
Diagnosis of a TB contact with active TB (one clinic
evaluation, one chest x-ray, and work-up)
$222
*Costs of ofﬁce visits were obtained from referring to the appropriate physician fees
as listed in the BCMA 2004 physician payment guide. No additional “clinic fee” for
overhead and administrative costs associated with clinic visits was incorporated into
the deﬁnition of costs.
AST, aspartate transaminase; INH, isoniazid; LTBI, latent tuberculosis infection.
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active TB case was more than $10,000 for the test and
treat intervention and more than $100,000 for the
treat all intervention. For the household contacts age
<10 years, the treat all intervention dominated the
other two options, similar to the results when QALY
was the health outcome.
Optimal Policy
Based on the results of the previous analysis, the
optimal policy could be formulated in this way: test
and treat all contacts, except the nonhousehold, non-
aboriginal contacts age >10 years, for whom no
screening is required, and treat all household contacts
age <10 years without screening. This policy results in
$463 cost, 4.6176 QALYs, and 0.040 risk of TB reac-
tivation per contact over the time horizon of 6 years.
These ﬁgures can be compared with no screening and
test and treat policies whose costs and outcomes are
presented in the bottom row of Table 4. Compared
with the test and treat (current) policy, the optimal
policy resulted in $27 cost-saving and a slight decrease
in QALY (<0.0001). In other words, for each one
QALY lost, the optimal policy resulted in saving of
$386,870.
PSA
The cost-effectiveness plane presenting the distribution
of the incremental costs and effects (as measured in
QALYs) comparing the test and treat versus no screen-
ing policies are presented in Figure 2a. The current
policy was dominant in 74% of iterations. Figure 2b
illustrates the cost-effectiveness plane for the optimal
policy versus the test and treat policy. In line with the
base case results, the optimal policy results in cost
savings and a slight decrease in QALYs; hence, the bulk
of the data lies in the south-west quadrant of the plane.
The CEAC comparing three policies is presented in
Figure 3a. Across a wide range of WTP thresholds, the
optimal policy was the best option to choose. At the
threshold of $50,000 per QALY, the optimal policy
had more than 90% chance of being the most cost-
effective policy. The CEAC of the three policies when
the assumption of positive correlation among utilities
was relaxed are presented in Figure 3b. Such assump-
tion did not substantially change the shape of CEAC.
One-Way Sensitivity Analyses
Results of the one-way sensitivity analysis are pre-
sented in Table 5. Results are robust with respect to the
majority of different assumptions evaluated, and the
optimal policy remained cost-effective compared with
the current policy in all scenarios. The biggest change
happened when the utility of LTBI therapy in the
absence of major adverse events was assumed to be
equal to the utility of no infection, which resulted in
the incremental net monetary beneﬁt of the optimal
policy dropping to $7. In this scenario, and whenTa
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higher compliance to isoniazid (INH) therapy was
assumed, the test and treat policy in the reference
group became the most cost-effective option. The pre-
ferred intervention in other subgroups of contacts did
not change in any scenario analyzed.
Discussion
Prioritizing candidates for LTBI treatment is an im-
portant challenge today as public health programs
compete for resources in a world of frozen or decreas-
ing budgets. Despite the overall economic and human
toll of TB disease, the lifetime risk of illness in newly
infected persons is, by a common estimate, 5% to 10%
[4]. For the large majority of TB infected persons who
never develop TB disease, LTBI treatment provides
virtually no beneﬁt while incurring the risk of hepato-
toxicity. In this economic evaluation, we found
support for the current recommendation of LTBI treat-
ment for TB contacts with a TST size 5 mm. Never-
theless, the current screening policy could be improved
signiﬁcantly, by excluding low risk groups from the
contact investigation and initiating preventive therapy
to high risk groups without screening. Applying these
results to the approximately 3500 contacts annually
screened in BC under current policy, such optimal
policy will result in 2240 less TST tests with only 0.6
extra cases of active TB, and an overall reduction of
$60,000 in the annual costs to the health-care system.
In addition, we believe such reduction in the workload
relating to screening could be transferred to greater
scrutiny and follow-up of the other high risk groups
identiﬁed.
We are not aware of any other study investigating
the cost-effectiveness of screening in subgroups of con-
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Figure 2 Cost-effectiveness planes comparing test and treat versus no screening (a) and optimal policy versus test and treat (b). Scatter plot displaying the
incremental cost and effectiveness pairs result from 1000 iterations of the model comparing.As can be seen in the left panel, most simulations resulted
in improvement in effectiveness (QALYs) at a reduction in costs when the. In the right panel, all simulations resulted in reducing costs at the expense of
a modest decrease in QALY.The line in both panels represents the cutoff value for willingness-to-pay of $50,000/QALY. QALY, quality-adjusted life year.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 25000 50000 75000 100000 125000 150000 175000
Value of ceiling ratio
P
ro
b
ab
ili
ty
 o
f 
co
st
-e
ff
ec
ti
ve
n
es
s
Optimal strategy
No screening strategy
Test and treat (current) strategy
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 25000 50000 75000 100000 125000 150000 175000
Value of ceiling ratio
P
ro
b
ab
ili
ty
 o
f 
co
st
-e
ff
ec
ti
ve
n
es
s
Optimal strategy
No screening strategy Test and treat (current) strategy
(a) (b)
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tacts with different risk factors. Previous studies have
focused on the cost-effective of screening [11] and
preventive therapy [41] in close contacts, and found
the policy to be cost-saving. In our analysis, screening
in all subgroups of household contacts was also
cost-saving. The current guideline of the US CDC on
contact investigation also recognizes close contacts
and children <5 y/o as high priority contacts [32], a
recommendation endorsed by our ﬁndings. In addi-
tion, we found that contacts with both of the above
conditions (household contacts aged <10 y/o) should
receive preventive therapy without screening.
We believe there are different reasons why in some
subgroups of contacts screening might not be cost-
effective. For the reference group (Canadian-born,
nonaboriginal, nonhousehold contacts age >10 y/o),
the risk of acquiring LTBI and/or developing TB is
probably too low to justify screening. The other
groups for whom screening was not cost-effective
are either foreign-born, or BCG-vaccinated contacts.
Besides the lower risk of disease transmission, the low
speciﬁcity of TST, especially at the 5 mm cutoff, might
have been responsible for lack of beneﬁt for screening
in these groups. As such, it may be that newer diag-
nostic screening tests for LTBI which are less affected
by BCG and atypical mycobacterial infection improve
the beneﬁt observed.
This study has several strengths. It is the ﬁrst CEA
in TB to measure health outcomes in QALYs con-
structed from utility values that are: 1) based on the
responses of both LTBI and active TB patients; and 2)
elicited using multiattribute utility instruments cali-
brated to society’s preferences. The vast majority of TB
CEAs have measured health outcomes in TB incidence,
completely discounting the risk of hepatoxicity (and its
impact on quality of life) from LTBI treatment. Those
using QALYs have relied upon utility values derived
from the opinion of clinicians [8,13,41,42]. Yet, clini-
cians may underestimate the capacity of patients, over
time, to adapt to declines in health [29,43]. As well,
the US Panel on Cost-Effectiveness in Health and
Medicine recommends that QALYs be grounded in
societal values, and clinicians’ views may not be rep-
resentative of all society. The analysis also uses both
HUI-3 and SF-6D 3 utilities. Some studies have sug-
gested that choice of preference elicitation method can
affect estimates of cost-effectiveness [44,45]. Neverthe-
less, we found the impact of this to be negligible in our
outcomes.
This analysis is the ﬁrst to use estimates of the risk
of progressing from LTBI to active TB obtained from a
multivariable regression of a large, population-based
database. For estimates of this risk, previous cost-
effectiveness studies in TB have relied upon large, clini-
cal trials designed to measure the efﬁcacy of BCG
or LTBI [7–10,14,46–49]; and observational studies
involving at-risk populations, such as HIV-seropositive
persons [6,7,11,13,48–52]. The possibility of obtain-
ing adjusted covariates and probability of positive TST
for speciﬁc subgroups of contacts enables an analysis
of cohort of contacts with a different combination of
factors determining TST performance and risk of TB
reactivation.
Our study raises an important issue relating to the
quality of life in patients who receive treatment for
LTBI. In sensitivity analyses, we found that a small
difference in the utilities associated with LTBI treat-
ment, and with foregoing it, could have large effects on
the cost-effectiveness of the intervention. To illustrate:
suppose that 1000 TB contacts received a 9-month
course of LTBI treatment without major hepatotoxic
event. If the utility of this treatment health state was
0.01 lower than no infection, preventive therapy may
be said to produce a loss of (0.01)(1000) = 10 QALYs.
By comparison, the year-long decrement in utility asso-
ciated with active TB disease was 0.1 (in survivors) in
our model. For a TB contact population with a 6-year
risk of TB of 6%, assuming a 100% reduction in TB
incidence because of treatment, LTBI therapy may
be said to produce a gain of (0.06)(0.1)(1000) =
6 QALYs. Hence, a decrement in quality of life which
is small, yet experienced by many, can outweigh an
Table 5 One-way sensitivity analysis of the incremental net beneﬁt (QALY as outcome), of the test and treat versus no screening and
optimal policy versus test and treat policy
Test and treat vs. no screening Optimal policy vs. test and treat
DCost DQALY DATB INMB# DCost DQALY DATB INMB*
Base case model -121 0.0013 -0.0161 187 -27 0.0000 0.0002 25
Third-party payer perspective -107 0.0013 -0.0161 172 -25 0.0000 0.0002 19
Time horizon 10 years -124 0.0021 -0.0182 229 -17 -0.0001 0.0002 15
Treatment initiation and completion 75% and 75% -253 0.0027 0.0198 388 -20 0.0000 0.0001 20
Discount rate 6% -118 0.0013 -0.0160 183 -20 -0.0001 0.0001 20
Starting age 45† -117 0.0013 -0.0160 182 -20 -0.0001 0.0001 24
HUI-3 utilities -121 0.0016 -0.0161 201 -27 0.0000 0.0002 27
Utility of LTBI treatment equal to the utility of no infection -121 0.0028 -0.0161 261 -27 -0.0002 0.000 7
*With QALY as the effectiveness outcome and with willingness-to-pay of $50,000/QALY.
†For contacts with age 10 y/o.
ATB, probability of developing active tuberculosis; HUI-3, Health Utilities Index-3; INMB, incremental net monetary beneﬁt; LTBI, latent tuberculosis infection; QALY,
quality-adjusted life year.
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increment in quality of life which is large yet experi-
enced by few. This is despite the fact that difference
in utilities between no infection and LTBI treatment
were not signiﬁcantly different in either a statistical
(P > 0.10) or clinical sense. There may exist a thresh-
old level of total beneﬁt above which society would
prefer the distribution of the total across many people,
but below which society would prefer its concentration
in a few people [53–56]. If so, we suggest the magni-
tude of health beneﬁts relevant here falls below this
threshold. If society would prefer the concentration of
LTBI treatment beneﬁts in a relatively small number
of individuals (persons spared TB disease) to the dis-
persed beneﬁts associated with no LTBI treatment (the
avoidance of LTBI treatment), the assumption of equal
utility might be more reasonable. It seems more
research is needed to clarify where society sets this
threshold.
Another methodological issue worthy of attention is
the shape of the CEAC observed in Figure 2. Despite
the fact that the test and treat policy was dominant
compared with no screening policy, its probability of
cost-effectiveness was below the no screening policy at
all levels of willingness to pay. A careful analysis of the
results of the second-order simulation revealed this
seemingly conﬂicting result to be due to the superiority
of the optimal policy combined with its high correla-
tion with the test and treat policy (correlation coefﬁ-
cient >0.98 for all costs and effectiveness outcomes). In
the second-order simulations, whenever the test and
treat policy had a higher net beneﬁt than the no screen-
ing policy, the optimal policy had also higher net
beneﬁt than the test and treat policy, giving it no
chance of being the best option. As mentioned by
previous authors, the CEAC only illustrates the prob-
ability of a policy being the best option and the choice
of the best policy should be made according to their
ranking in expected ICER or NMB [57–58].
There were a number of limitations to our study.
For purposes of analytical feasibility and applicability
of the results for the decision-maker, we had to exclude
some covariates known to affect risk of TB infection
such as certain medical conditions and the infectious-
ness of the source case. Nevertheless, based on our
population-based approach, the rare occurrence of
excluded covariates does not limit the generalizability
of our results. Another limitation was that only TST at
cutoff of 5 mm was considered for this analysis. TST at
this cutoff has high sensitivity but suffers from poor
speciﬁcity [59]. The low speciﬁcity means that many
contacts that test positive are not infected, which is
translated into a reduced hazard ratio of TB reactiva-
tion. It could be argued that TST at a higher cutoff
point (e.g., 10 mm or 15 mm) might be a cost-effective
alternative for contacts at low risk of TB reactivation
as fewer contacts will undergo unnecessary preventive
therapy. An optimal policy, therefore, might recom-
mend higher cutoffs for subgroups of contacts at lower
risk of infection. In addition, from a practical perspec-
tive, it might be difﬁcult to convince the decision-
maker to forego preventive therapy for some contacts
without screening. Unfortunately, the format of the
data available for this analysis did not let us analyze
other cutoff points for low risk groups but this ques-
tion could be the focus of further research.
There was some bias in our model in favor of the
policy of no LTBI treatment. First, the additional costs
of rehospitalization and of treating active TB disease
in patients with comorbidities were not considered.
Second, a full course of LTBI treatment was deﬁned as 9
months, but, with the available data, it was possible to
know only whether TB contacts received 6 months or
more of therapy. Thus, our estimate of treatment effec-
tiveness, a 94% reduction in TB incidence, could have
been too low. The effect was likely small though. In
subjects, with a high level of adherence, who completed
12 months of INH in a large US trial, a 93% reduction
in TB incidence was observed [60]. Third, the base-case
analyses assumed a time horizon of 6 years, but LTBI
increases the lifetime risk of TB [61] and INH’s protec-
tive effect lasts more than 19 years [62]. The risk
developing active TB is highest in the 2 to 3 years after
infection [16,17,20], however, and one-way sensitivity
analysis showed a longer time horizon affected cost-
effectiveness by little.One of the only base-case assump-
tions possibly favoring LTBI treatment was that partial
LTBI therapy would reduce TB incidence by 65%. In
6956 Eastern European patients with pulmonary
ﬁbrotic lesions, a 3-month course of isoniazid reduced
TB incidence by only 21% [63]. Substitution of this
lower value in the model lowered the probability of
treatment cost-effectiveness by 1% to 9%over theWTP
range of $0 to $200,000 per QALY gained, which we
consider to be a modest impact.
A natural extension of this analysis is to develop
an evidence-based guideline informed from a cost-
effectiveness model to assign a risk score to contacts
based on the presence or absence of important covari-
ates. The screening approachwould then be determined
by comparing the overall score with predetermined
threshold values. For example, four different thresholds
could be placed on the overall score to indicate ﬁve
different interventions: excluding a contact from
screening, providing preventive therapy to TST positive
contacts at cutoff points of 5 mm, 10 mm, or 15 mm, or
providing preventive therapy without screening. The
cost-effectiveness of the overall guidelines can then be
evaluated with respect to the current policy.
Conclusion
We evaluated the cost-effectiveness of LTBI therapy,
versus none, for household TB contacts and found
overall support for the current practice of providing
treatment on the basis of TST size. Nevertheless, for
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certain groups of contacts, screening might be unnec-
essary, and for high risk groups, it might be justiﬁed to
start preventive treatment without screening.
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